Liu Kaixiong, Liu Dong, Feng Yun, Zhang Hongying, Zeng Dunhuan, Liu Qinhua, Qu Jieming
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ann Transl Med. 2020 Aug;8(16):986. doi: 10.21037/atm-20-4404.
Spliceosome-associated protein 130 (SAP130), a novel danger-associated molecular pattern (DAMP), is involved in inflammatory disease. However, no data are available about SAP130 in idiopathic pulmonary fibrosis (IPF). Our study aimed to investigate SAP130 in the serum and lung tissue of patients with IPF and to determine its clinical significance.
SAP130 levels in the serum of 83 IPF patients and 38 healthy subjects were measured. Additionally, immunohistochemical staining for SAP130 was performed in lung specimens of IPF patients and control subjects. Correlation between serum SAP130 levels and clinical parameters were investigated.
Serum SAP130 levels were elevated in IPF patients compared with healthy controls. In parallel, the expression of SAP130 in lung tissue was elevated in IPF. SAP130 levels were higher in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) than patients with stable IPF (P=0.0144). The area under curve (AUC) of the ROC curve for the diagnosis of IPF was 0.944 (95% CI, 0.810-0.997) for SAP130. The sensitivity (92.1%) and specificity (69.9%) were obtained for the cutoff value of 643.87 pg/mL. In patients with stable IPF, the SAP130 level correlated positively with fibrosis on high-resolution CT (HRCT) (r=0.4164, P=0.0029) and serum KL-6 (r=0.4564, P=0.0010), and inversely with FEV1 (r=-0.3562, P=0.0120) and DLCO (r=-0.5550, P<0.0001). In patients with AE-IPF, the SAP130 level correlated positively with fibrosis (r=0.3735, P=0.0296) and ground-glass opacity (r=0.4697, P=0.0051) on HRCT and serum Krebs von den Lungen 6 (KL-6) (r=0.5470, P= 0.0008).
The study suggested that SAP130 was a potential noninvasive biomarker that correlates well with disease severity of IPF. A prospective, multicentre study is required to validate the clinical and pathophysiological utility of SAP130 in IPF.
剪接体相关蛋白130（SAP130）是一种新型的危险相关分子模式（DAMP），参与炎症性疾病。然而，关于特发性肺纤维化（IPF）中SAP130的数据尚无报道。我们的研究旨在调查IPF患者血清和肺组织中的SAP130，并确定其临床意义。
测量了83例IPF患者和38例健康受试者血清中的SAP130水平。此外，对IPF患者和对照受试者的肺标本进行了SAP130免疫组化染色。研究了血清SAP130水平与临床参数之间的相关性。
与健康对照相比，IPF患者血清SAP130水平升高。同时，IPF患者肺组织中SAP130的表达也升高。特发性肺纤维化急性加重（AE-IPF）患者的SAP130水平高于稳定期IPF患者（P=0.0144）。SAP130诊断IPF的ROC曲线下面积（AUC）为0.944（95%CI，0.810-0.997）。截断值为643.87 pg/mL时，敏感性为92.1%，特异性为69.9%。在稳定期IPF患者中，SAP130水平与高分辨率CT（HRCT）上的纤维化（r=0.4164，P=0.0029）和血清KL-6（r=0.4564，P=0.0010）呈正相关，与第一秒用力呼气容积（FEV1）（r=-0.3562，P=0.0120）和一氧化碳弥散量（DLCO）（r=-0.5550，P<0.0001）呈负相关。在AE-IPF患者中，SAP130水平与HRCT上的纤维化（r=0.3735，P=0.0296）和磨玻璃影（r=0.4697，P=0.0051）以及血清克雷伯斯-冯-登-伦根6（KL-6）（r=0.5470，P=0.0008）呈正相关。
该研究表明，SAP130是一种潜在的非侵入性生物标志物，与IPF的疾病严重程度密切相关。需要进行一项前瞻性、多中心研究来验证SAP130在IPF中的临床和病理生理效用。
